




The relative strengths and weaknesses of Chemomab Therapeutics Ltd are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemomab Therapeutics Ltd compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 195% points. The greatest weakness of Chemomab Therapeutics Ltd is the variable Stockholders Equity, reducing the Economic Capital Ratio by 152% points.

The company's Economic Capital Ratio, given in the ranking table, is 391%, being 153% points above the market average of 238%.

Input Variable	Value in 1000 USD
Assets, Current	18,211
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,121
Liabilities, Non-Current	725
Other Assets	1,386
Other Compr. Net Income	54,248
Other Expenses	3,350
Other Liabilities	0
Other Net Income	4,226
Other Revenues	0
Property and Equipment	158
Research and Development	13,303
Selling, General and Administrative Expense	6,245

Output Variable	Value in 1000 USD
Assets	19,755
Liabilities	4,846
Expenses	22,898
Revenues	0
Stockholders Equity	14,909
Net Income	-18,672
Comprehensive Net Income	8,452
BaseVar	52,986
ECR before Limited Liability	333%
Economic Capital Ratio	391%